West Pharmaceutical Services Inc. Archives

West Pharmaceutical Services beats Street in Q3, raises guidance

West Pharmaceutical Services (NYSE:WST) shares rose slightly today on third-quarter results that topped the consensus forecast.

The Exton, Pennsylvania-based company posted profits of $175.6 million, or $2.31 per share, on sales of $706.5 million for the three months ended Sept. 30, 2021, more than doubling its bottom-line on sales growth of 28.9%.

Adjusted to exclude one-time items, earnings per share were $2.06, 26¢ ahead of Wall Street, where analysts were looking for sales of $687.1 million.

Get the full story at our sister site, Drug Delivery Business News.

West Pharmaceutial Services beats The Street, raises guidance

West Pharmaceutical Services (NYSE:WST) shares ticked up before hours on second-quarter results that beat the consensus forecast.

The Exton, Pa.-based company posted profits of $187.3 million, or $2.47 per share, on sales of $723.6 million for the three months ended June 30, 2021, more than doubling its bottom-line on sales growth of 37.3%.

Get the full story at our sister site, Drug Delivery Business News.

West Pharmaceutical Services beats Street in Q1, raises guidance

West Pharmaceutical Services (NYSE:WST) posted Street-beating first-quarter financial results and raised its full-year guidance for 2021.

The Exton, Pa.-based company posted profits of $151.2 million, or $1.99 per share, on sales of $670.7 million for the three months ended March 31, 2021, more than doubling its bottom-line on sales growth of 36.5%.

Get the full story at our sister site, Drug Delivery Business News.

Medtech stocks help boost S&P rally

Medtech stocks helped the S&P 500 Index reach record highs today amid a bounceback from the lows of the COVID-19 pandemic.

Reuters reported that medtech played its part in the record turn of the market, with Abiomed (NSDQ:ABMD), Regeneron Pharmaceuticals (NSDQ:REGN) and West Pharmaceutical Services (NYSE:WST), all of which are involved in developing COVID-19 therapeutics, all rising more than 50% since the index’s previous record high before the pandemic in February.

The report attributed the S&P’s rise in part to the economic stimulus in response to the pandemic, as the index has risen more than 50% from its low on March 23 and is up nearly 5% for the year so far.

Currently, the S&P 500 is up 0.2% for the day at 3,389.78 points.

Medtech’s part in the S&P 500’s rise falls in line with the performance of MassDevice’s MedTech 100 Index, which includes stocks of the world’s largest medical device co…